Antiretrovirals; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. (ATC-Code: J05AF03).
Mechanism of action
Inhibits HIV viral enzyme reverse transcriptase and DNA synthesis causing chain termination.
Therapeutic use
Treatment of HIV infection in combination with other antiretroviral agents.
Pregnancy and lactiation implications
Should not be used in pregnant women unless other alternatives unavailable (lack of data and concerns regarding teratogenicity in animals). Unknown whether distributed into human milk (not recommended during lactation).
Unlabeled use
Contraindications
Hypersensitivity to zalcitabine or any component of the formulation.
Warnings and precautions
Zalcitabine can cause severe peripheral neuropathy (use with extreme caution in pre-existing peripheral neuropathy; avoid use in moderate or severe peripheral neuropathy; use with caution in risk for developing peripheral neuropathy). Potentially fatal pancreatitis may occur. Cases of fatal lactic acidosis and severe hepatomegaly with steatosis may occur (use with extreme caution in hepatic impairment and in risk factors for liver disease). Hepatic failure and death (may be related to underlying hepatitis B) reported (rare). Oral ulceration and rare esophageal ulcers reported. Use with caution in renal dysfunction. Multiple potentially serious drug interactions exist. Use with caution in history of heart failure (cardiomyopathy and heart failure reported). Fat redistribution and accumulation observed in patients receiving antiretroviral agents (causal relationship not established).